In April 2026, Canada’s Drug Agency (CDA) unveiled an expanded dataset, offering a comprehensive look at the trends and intricacies…
Read More
Opdivo Secures Landmark US and EU Approvals for Classical Hodgkin Lymphoma Across Pediatric and Adult Populations
Bristol Myers Squibb’s (BMS) groundbreaking immunotherapy, Opdivo (nivolumab), has achieved a significant milestone with dual approvals from the U.S. Food…
Read MoreYOU MAY HAVE MISSED
